Next Science Limited, a medical technology company, researches, develops, and commercializes non-toxic technology products with efficacy in eradicating biofilm based and free-floating bacteria in the United States and Australia. More Details
Flawless balance sheet with limited growth.
Share Price & News
How has Next Science's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NXSC.F's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: NXSC.F underperformed the US Medical Equipment industry which returned 17.1% over the past year.
Return vs Market: NXSC.F underperformed the US Market which returned 15.8% over the past year.
Price Volatility Vs. Market
How volatile is Next Science's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Next Science undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NXSC.F's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate NXSC.F's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: NXSC.F is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: NXSC.F is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NXSC.F's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NXSC.F is overvalued based on its PB Ratio (12.6x) compared to the US Medical Equipment industry average (4x).
How is Next Science forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NXSC.F is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NXSC.F is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NXSC.F is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NXSC.F's revenue (57.9% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: NXSC.F's revenue (57.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NXSC.F's Return on Equity is forecast to be high in 3 years time
How has Next Science performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NXSC.F is currently unprofitable.
Growing Profit Margin: NXSC.F is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NXSC.F is unprofitable, and losses have increased over the past 5 years at a rate of 33.3% per year.
Accelerating Growth: Unable to compare NXSC.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NXSC.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.8%).
Return on Equity
High ROE: NXSC.F has a negative Return on Equity (-98.21%), as it is currently unprofitable.
How is Next Science's financial position?
Financial Position Analysis
Short Term Liabilities: NXSC.F's short term assets ($12.8M) exceed its short term liabilities ($1.8M).
Long Term Liabilities: NXSC.F's short term assets ($12.8M) exceed its long term liabilities ($1.8M).
Debt to Equity History and Analysis
Debt Level: NXSC.F is debt free.
Reducing Debt: NXSC.F had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NXSC.F has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NXSC.F has sufficient cash runway for 2.3 years if free cash flow continues to grow at historical rates of 9.6% each year.
What is Next Science current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NXSC.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NXSC.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NXSC.F's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NXSC.F's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NXSC.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ms. Judith Mitchell serves as Managing Director & CEO of Next Science Limited since August 2017 and serves as its a Director since October 20, 2017. Previously, Ms. Mitchell was President, DePuy Synthes As ...
CEO Compensation Analysis
Compensation vs Market: Judith's total compensation ($USD431.91K) is below average for companies of similar size in the US market ($USD1.35M).
Compensation vs Earnings: Insufficient data to compare Judith's compensation with company performance.
|MD, CEO & Director||3.08yrs||US$431.91k||2.51% |
|Founder & CTO||no data||US$349.58k||10.98% |
|Chief Financial Officer||no data||US$210.29k||no data|
|Chief Operating Officer||2.25yrs||US$341.74k||no data|
|Chief Commercial Officer||0.25yr||no data||no data|
|Company Secretary||2.25yrs||no data||no data|
Experienced Management: NXSC.F's management team is considered experienced (2.3 years average tenure).
|MD, CEO & Director||3.08yrs||US$431.91k||2.51% |
|Independent Non-Executive Chairman||2.17yrs||US$226.05k||0.33% |
|Independent Non-Executive Director||1.92yrs||US$97.12k||0.066% |
|Non-Executive Director||8.42yrs||US$101.82k||no data|
|Independent Non-Executive Director||2.92yrs||US$80.89k||0.026% |
|Independent Non-Executive Director||1.92yrs||US$97.12k||0.024% |
Experienced Board: NXSC.F's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Next Science Limited's company bio, employee growth, exchange listings and data sources
- Name: Next Science Limited
- Ticker: NXSC.F
- Exchange: OTCPK
- Founded: 2012
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: AU$237.149m
- Listing Market Cap: AU$167.360m
- Shares outstanding: 188.21m
- Website: https://www.nextscience.com
- Next Science Limited
- The Zenith Building, Tower A
- Suite 1902
- New South Wales
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NXS||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Apr 2019|
|NXS||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Apr 2019|
|NXSC.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Apr 2019|
Next Science Limited, a medical technology company, researches, develops, and commercializes non-toxic technology products with efficacy in eradicating biofilm based and free-floating bacteria in the Unite ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/29 00:15|
|End of Day Share Price||2020/09/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.